GCIA
NKGN

Gabelli & Co Investment Advisers’s NKGen Biotech, Inc. Common Stock NKGN Stock Holding History

Gabelli & Co Investment Advisers’s Portfolio NKGN Stock Details NKGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-86,200
Closed -$890K – 268
2023
Q2 		$890K Hold
86,200
– – 0.15% 92
2023
Q1 		$873K Hold
86,200
– – 0.17% 83
2022
Q4 		$858K Hold
86,200
– – 0.18% 88
2022
Q3 		$840K Hold
86,200
– – 0.11% 141
2022
Q2 		$837K Hold
86,200
– – 0.11% 147
2022
Q1 		$836K Hold
86,200
– – 0.11% 150
2021
Q4 		$833K Hold
86,200
– – 0.11% 146
2021
Q3 		$835K Buy
+86,200
New +$840K 0.1% 151

Other funds holding NKGN

MC
Meteora Capital Boca Raton, Florida $1.36B AUM 20.06% 1-Year Est. Return
RCM
Rivernorth Capital Management West Palm Beach, Florida $2B AUM 0.79% 1-Year Est. Return
SIM
Sandia Investment Management Boston, Massachusetts $40.1M AUM 13.88% 1-Year Est. Return
DC
Diametric Capital Boston, Massachusetts $385M AUM 31.7% 1-Year Est. Return
PC
Periscope Capital Toronto, Ontario, Canada $902M AUM 6.27% 1-Year Est. Return
KIM
Karpus Investment Management Pittsford, New York $3.21B AUM 6.83% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
AIMCA
Alberta Investment Management Corp (AIMCo) Edmonton, Alberta, Canada $17.9B AUM 27.57% 1-Year Est. Return
MTCM
Mint Tower Capital Management Amsterdam, Netherlands $1.12B AUM 18.84% 1-Year Est. Return
WCMNY
Westchester Capital Management (New York) Valhalla, New York $2.21B AUM 26.02% 1-Year Est. Return

Gabelli & Co Investment Advisers's NKGN Position: Q3 2023 in Review

Gabelli & Co Investment Advisers sold out of NKGen Biotech, Inc. Common Stock (NKGN) in Q3 2023, closing a stake of 86,200 shares — an estimated $890K sold.

Gabelli & Co Investment Advisers first reported a position in NKGN in Q3 2021 and held it in 8 quarters. The position peaked at $890K in Q2 2023. 13 funds tracked by Wall St. Rank hold NKGN as of Q3 2023.

  • Gabelli & Co Investment Advisers reported no remaining NKGen Biotech, Inc. Common Stock position as of Q3 2023 after selling out during the quarter.
  • Gabelli & Co Investment Advisers sold 86,200 NKGen Biotech, Inc. Common Stock shares in Q3 2023, an estimated $890K.
  • Gabelli & Co Investment Advisers first reported a position in NKGen Biotech, Inc. Common Stock in Q3 2021 and held it in 8 quarters.
  • Gabelli & Co Investment Advisers's NKGen Biotech, Inc. Common Stock position peaked at $890K in Q2 2023.
  • 13 funds tracked by Wall St. Rank held NKGen Biotech, Inc. Common Stock as of Q3 2023.

Based on Gabelli & Co Investment Advisers's 13F filing for Q3 2023, filed 8 Nov 2023.